Scoring system devised for stratifying children with suspected Sjögren’s syndrome
Researchers have devised the Florida Scoring System to help clinicians stratify children with suspected Sjögren’s syndrome into three distinct classes, thereby improving diagnosis and disease monitoring.
SMA newborn screening improves functional outcomes
Children diagnosed with spinal muscular atrophy through a newborn screening initiative have better functional outcomes than their peers diagnosed after the development of clinical symptoms, the SMARTCARE study findings show.
‘No substantive increase’ in ASD with prenatal topiramate exposure
Children born to women with epilepsy who take topiramate during the second half of their pregnancy do not have a substantially increased risk of autism spectrum disorder, suggests research published in The New England Journal of Medicine.
Sepsis during paediatric leukaemia therapy linked to long-term neurocognitive dysfunction
Severe sepsis during treatment for childhood leukaemia may be associated with an increased risk of moderate-to-severe neurocognitive dysfunction in adulthood, US Study findings indicate.
Umbilical hernia repair ‘should be delayed’ until after age 5 years
The majority of umbilical hernias close spontaneously regardless of size, US researchers have found.
FOXO1 fusion status aids paediatric local rhabdomyosarcoma risk assessment
Considering FOXO1 fusion status improves the risk assessment of children with localised rhabdomyosarcoma, suggest study findings published in Cancer.
Home insulin pump use feasible for hospitalised children with type 1 diabetes
For children with type 1 diabetes who are admitted to hospital, continuing with a home insulin pump is feasible for the prevention of hyperglycemia and hypoglycemia, suggests research published in JAMA Network Open.
Bevacizumab addition to temozolomide chemotherapy may improve neuroblastoma response
Findings from the BEACON-Neuroblastoma trial suggest that adding bevacizumab to temozolomide-based chemotherapy may improve the objective response rate for children with high-risk, relapsed or refractory disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cerliponase alfa treatment shows extended efficacy for CLN2 disease
Cerliponase alfa treatment slows the progression of neuronal ceroid lipofuscinosis type 2 disease for at least 5 years, shows an open-label extension study in The Lancet Neurology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Zonulin shows biomarker potential for celiac disease in at-risk children
Serum levels of the protein zonulin, high levels of which are associated with increased intestinal permeability, may be a useful biomarker for the development of celiac disease autoimmunity in children at genetic risk of the condition, suggest findings from the CD-GEMMA study.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
